Novartis Announces Positive Findings for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia

Scemblix (asciminib) plus investigators’ choice of tyrosine kinase inhibitor showed clinically meaningful and statistically significant data in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Source link
#Novartis #Announces #Positive #Findings #Scemblix #Newly #Diagnosed #Chronic #Myeloid #Leukemia